A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy

We describe the first case report of a patient with COVID19 infection and metastatic breast cancer, while on systemic therapy with a CDK4/6 inhibitor. The patient had unique disease course, characterized with delayed symptomatology. The case highlights novel findings and stress careful and extended...

Descripción completa

Detalles Bibliográficos
Autores principales: Grinshpun, Albert, Merlet, Irit, Fruchtman, Hila, Nachman, Dean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295974/
https://www.ncbi.nlm.nih.gov/pubmed/32582559
http://dx.doi.org/10.3389/fonc.2020.01085
_version_ 1783546749634215936
author Grinshpun, Albert
Merlet, Irit
Fruchtman, Hila
Nachman, Dean
author_facet Grinshpun, Albert
Merlet, Irit
Fruchtman, Hila
Nachman, Dean
author_sort Grinshpun, Albert
collection PubMed
description We describe the first case report of a patient with COVID19 infection and metastatic breast cancer, while on systemic therapy with a CDK4/6 inhibitor. The patient had unique disease course, characterized with delayed symptomatology. The case highlights novel findings and stress careful and extended follow-up during COVID19 infection in patients taking biologic therapies affecting the immune system.
format Online
Article
Text
id pubmed-7295974
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-72959742020-06-23 A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy Grinshpun, Albert Merlet, Irit Fruchtman, Hila Nachman, Dean Front Oncol Oncology We describe the first case report of a patient with COVID19 infection and metastatic breast cancer, while on systemic therapy with a CDK4/6 inhibitor. The patient had unique disease course, characterized with delayed symptomatology. The case highlights novel findings and stress careful and extended follow-up during COVID19 infection in patients taking biologic therapies affecting the immune system. Frontiers Media S.A. 2020-06-09 /pmc/articles/PMC7295974/ /pubmed/32582559 http://dx.doi.org/10.3389/fonc.2020.01085 Text en Copyright © 2020 Grinshpun, Merlet, Fruchtman and Nachman. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Grinshpun, Albert
Merlet, Irit
Fruchtman, Hila
Nachman, Dean
A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy
title A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy
title_full A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy
title_fullStr A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy
title_full_unstemmed A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy
title_short A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy
title_sort protracted course of covid19 infection in a metastatic breast cancer patient during cdk4/6 inhibitor therapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295974/
https://www.ncbi.nlm.nih.gov/pubmed/32582559
http://dx.doi.org/10.3389/fonc.2020.01085
work_keys_str_mv AT grinshpunalbert aprotractedcourseofcovid19infectioninametastaticbreastcancerpatientduringcdk46inhibitortherapy
AT merletirit aprotractedcourseofcovid19infectioninametastaticbreastcancerpatientduringcdk46inhibitortherapy
AT fruchtmanhila aprotractedcourseofcovid19infectioninametastaticbreastcancerpatientduringcdk46inhibitortherapy
AT nachmandean aprotractedcourseofcovid19infectioninametastaticbreastcancerpatientduringcdk46inhibitortherapy
AT grinshpunalbert protractedcourseofcovid19infectioninametastaticbreastcancerpatientduringcdk46inhibitortherapy
AT merletirit protractedcourseofcovid19infectioninametastaticbreastcancerpatientduringcdk46inhibitortherapy
AT fruchtmanhila protractedcourseofcovid19infectioninametastaticbreastcancerpatientduringcdk46inhibitortherapy
AT nachmandean protractedcourseofcovid19infectioninametastaticbreastcancerpatientduringcdk46inhibitortherapy

Ejemplares similares